Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities

Exclusion Criteria

• •Patient suffering other skin disease resembling lichenoid skin lesions under anti-PD-1 therapy.
• •Acute psychiatric illness or acute crisis.
• •Contraindications to ruxolitinib, e.g. known hypersensitivity or allergy
• •Topical glucocorticosteroids, topical calcineurin inhibitors and UV light therapy are not allowed during the study or for 1 week before the study beginning. Other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine are not allowed during the study or for 8 weeks before the study beginning.
• •Women who are pregnant or breast feeding \*
• •Intention to become pregnant during the course of the study
• •Known or suspected non-compliance, drug or alcohol abuse.
• •Patients with an active, serious infection, including localized infections.
• •Inability to follow the procedures of the study due to language problems, psychological disorders, dementia of the participant.
• •Participation in another study with topical or oral ruxolitinib within the 30 days preceding and during the present study.
• •Previous enrolment into the current study.
• •Enrolment of the investigator, his/her family members, employees and other dependent persons.
• •* Participants must avoid pregnancy during the study. A blood pregnancy test is required before start of therapy, with regular urine tests throughout. Lactating individuals are ineligible.
• •Participants must use effective contraceptives, either:
• •An ovulation-inhibiting method (e.g., pill, injectable, implant, patch, or vaginal ring) or
• •An intrauterine device (IUD).
• •Contraception should extend one week post-study. If pregnancy occurs during or within one week after the study, participants should notify the overseeing physician immediately.